Collaborative Arrangement, Maximum Third Party Share Of Cost

No definition available.

Name:	cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost
Namespace Prefix:	cdtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Collaborative Arrangement, Rights And Obligations, Milestone Payments, Commercialization

+ References

No definition available.

+ Details

Name:	cdtx_CollaborativeArrangementRightsAndObligationsMilestonePaymentsCommercialization
Namespace Prefix:	cdtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Collaborative Arrangement, Rights And Obligations, Milestone Payments, Development And Regulatory

+ References

No definition available.

+ Details

Name:	cdtx_CollaborativeArrangementRightsAndObligationsMilestonePaymentsDevelopmentAndRegulatory
Namespace Prefix:	cdtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Direct Transaction Costs

+ References

No definition available.

+ Details

Name:	cdtx_DirectTransactionCosts
Namespace Prefix:	cdtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Payments Related To Collaborative Agreements

+ References

No definition available.

+ Details

Name:	cdtx_PaymentsRelatedToCollaborativeAgreements
Namespace Prefix:	cdtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Research And Development Expense, Acquired In Process

+ References

No definition available.

+ Details

Name:	cdtx_ResearchAndDevelopmentExpenseAcquiredInProcess
Namespace Prefix:	cdtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability

+ References

No definition available.

+ Details

Name:	cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability
Namespace Prefix:	cdtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 310
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481990/310-10-45-2

+ Details

Name:	us-gaap_AccountsReceivableNetCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 3
-SubTopic 10
-Topic 808
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479428/808-10-45-3

+ Details

Name:	us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of transaction price allocated to performance obligation that has not been recognized as revenue.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (a)
-SubTopic 10
-Topic 606
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-13

+ Details

Name:	us-gaap_RevenueRemainingPerformanceObligation
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Details

Name:	srt_CounterpartyNameAxis=cdtx_JanssenPharmaceuticalsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=us-gaap_LicenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=cdtx_UpfrontPaymentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=cdtx_MilestoneAchievementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

SIGNIFICANT AGREEMENTS AND CONTRACTS - Additional Information (Details) - USD ($)		3 Months Ended		6 Months Ended		38 Months Ended
	Apr. 24, 2024	Jun. 30, 2025	Jun. 30, 2024	Jun. 30, 2025	Jun. 30, 2024	Apr. 23, 2024	Dec. 31, 2024
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Acquired in-process research and development		$ 0	$ 84,883,000	$ 0	$ 84,883,000
Revenue from collaborative agreement		0	302,000	0	1,275,000
Accounts receivable		1,859,000		1,859,000			$ 1,694,000
Janssen Pharmaceuticals, Inc. \| Related Party \| Collaborative Arrangement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payments related to collaborative agreement						$ 27,000,000
Collaborative agreement, maximum cost share						47,800,000
Revenue from collaborative agreement			302,000		$ 1,275,000
Revenue, remaining performance obligation, amount		0		0
Accounts receivable		$ 0		$ 0			$ 0
Janssen Pharmaceuticals, Inc. \| License Agreement \| Related Party \| Collaborative Arrangement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payments related to collaborative agreement	$ 85,000,000
Milestone payment obligation, development and regulatory	150,000,000
Milestone payment obligation, commercialization	455,000,000
Acquired in-process research and development			85,400,000
Direct transaction costs			$ 400,000
Janssen Pharmaceuticals, Inc. \| License Agreement \| Upfront Payment \| Related Party \| Collaborative Arrangement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Acquired in-process research and development	$ 84,900,000
Contract liability						500,000
Janssen Pharmaceuticals, Inc. \| Milestone Achievement \| Related Party \| Collaborative Arrangement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue from collaborative agreement						$ 10,000,000